What is the Windlas Biotech Ltd share price today?

The share price of NSE:WINDLAS-EQ on 01 Oct 2026 (as of 15:05:16 IST) is ₹1082.9.

What is the NSE:WINDLAS-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:WINDLAS-EQ 52 week high low range shows a high of ₹1181.9 and a low of ₹697.4.

What is the Windlas Biotech Ltd market cap?

As on 01 Oct 2026, Windlas Biotech Ltd market cap is ₹22635900000.

What is the shareholding pattern of Windlas Biotech Ltd Stock?

The shareholding pattern of Windlas Biotech Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 63.31% Foreign Institutional Investors (FII): 2.04% Domestic Institutional Investors (DII): 4.08% Mutual Funds: 5.76% Retail & Others: 24.81% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Windlas Biotech Ltd?

The Price-to-Earnings (PE) ratio of Windlas Biotech Ltd is 34.0615, and the Price-to-Book (PB) ratio is 2.7743, as on 01 Oct 2026.

Windlas Biotech Share Price

879.60-30.05 (-3.30%)

-6.97% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-3.30%

1 Week

-4.74%

1 Month

-18.74%

3 Month

+2.66%

6 Month

+2.93%

YTD

+10.63%

1 Year

-6.97%

5 Year

+182.97%

10 Year

Max

+101.28%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

877.05

861.00

858.00

808.05

746.55

697.40

High

919.00

921.70

1094.10

1181.90

About

Windlas Biotech Limited provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world. The company is amongst the top five Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

LAURUSLABSNSE

ZYDUSLIFENSE

DRREDDYNSE

CIPLANSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

WINDLASNSE

LTP

1W Low

1W High

Market cap (₹)

1769.9+8.9 (0.51%)

1722

1855

4,24,202Cr

10064+400 (4.14%)

9621.50

10064

2,64,141Cr

4650+70 (1.53%)

4532

4675

1,74,402Cr

2323+79 (3.52%)

2206.10

2441.90

1,26,811Cr

1240.6+56.2 (4.75%)

1182

1254.20

1,23,685Cr

1368.3+23.3 (1.73%)

1336.70

1368.30

1,11,868Cr

1396.9+38.9 (2.86%)

1357

1396.90

1,11,650Cr

2475+5.7 (0.23%)

2457.90

2528

1,02,196Cr

1694.5+34.6 (2.08%)

1647.20

1697.40

96,951Cr

2015.9+26 (1.31%)

1974

2033.80

91,301Cr

879.8-43.6 (-4.72%)

861

921.70

1,874Cr

Windlas Biotech Share Price

879.60-30.05 (-3.30%)

-6.97% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years16%

3 years21%

Last year19%

Compounded Profit Growth

10 years-

5 years33%

3 years16%

Last year9%

Stock Price CAGR

10 years-

5 years24%

3 years35%

1 year-4%

Return on Equity

10 years14%

5 years13%

3 years13%

Last year13%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	16%	21%	19%
-	33%	16%	9%
-	24%	35%	-4%
14%	13%	13%	13%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

LAURUSLABS

ZYDUSLIFE

DRREDDY

CIPLA

MANKIND

AUROPHARMA

LUPIN

WINDLAS

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,769.9	₹424202 Cr	38.68	8.29	58.23	₹11479 Cr
10,064	₹264141 Cr	90.3	34.04	128.41	₹2568 Cr
4,650	₹174402 Cr	82.11	14.04	106.21	₹2163 Cr
2,323	₹126811 Cr	94.64	8.17	33.94	₹889 Cr
1,240.6	₹123685 Cr	27.41	9.42	62.53	₹5040 Cr
1,368.3	₹111868 Cr	39.95	11.08	59.2	₹4196 Cr
1,396.9	₹111650 Cr	38.54	10.86	52.6	₹3879 Cr
2,475	₹102196 Cr	45.57	17.23	76.26	₹1913 Cr
1,694.5	₹96951 Cr	26.11	17.95	96.84	₹3505 Cr
2,015.9	₹91301 Cr	16.51	30.95	154.35	₹5333 Cr
879.8	₹1874 Cr	28.2	7.58	47.1	₹66 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020
₹248 Cr	₹238 Cr	₹233 Cr	₹222 Cr	₹210 Cr	₹203 Cr	₹195 Cr	₹187 Cr	₹175 Cr	₹171 Cr	₹162 Cr	₹153 Cr	₹145 Cr	₹141 Cr	₹120 Cr	₹133 Cr	₹120 Cr	₹122 Cr	₹118 Cr	₹115 Cr	₹111 Cr	₹107 Cr	₹117 Cr	₹101 Cr	₹102 Cr
₹5 Cr	₹4 Cr	₹5 Cr	₹4 Cr	₹5 Cr	₹5 Cr	₹4 Cr	₹5 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹1 Cr	₹69 L	₹79 L	₹99 L	₹62 L	₹69 L
₹253 Cr	₹243 Cr	₹238 Cr	₹226 Cr	₹215 Cr	₹208 Cr	₹199 Cr	₹192 Cr	₹179 Cr	₹176 Cr	₹165 Cr	₹156 Cr	₹147 Cr	₹143 Cr	₹122 Cr	₹135 Cr	₹123 Cr	₹125 Cr	₹119 Cr	₹116 Cr	₹112 Cr	₹108 Cr	₹118 Cr	₹102 Cr	₹103 Cr
₹229 Cr	₹221 Cr	₹216 Cr	₹201 Cr	₹191 Cr	₹185 Cr	₹177 Cr	₹170 Cr	₹160 Cr	₹153 Cr	₹145 Cr	₹137 Cr	₹131 Cr	₹128 Cr	₹109 Cr	₹120 Cr	₹109 Cr	₹111 Cr	₹108 Cr	₹105 Cr	₹102 Cr	₹99 Cr	₹103 Cr	₹92 Cr	₹91 Cr
₹32 Cr	₹30 Cr	₹29 Cr	₹32 Cr	₹32 Cr	₹30 Cr	₹28 Cr	₹28 Cr	₹25 Cr	₹26 Cr	₹24 Cr	₹22 Cr	₹20 Cr	₹19 Cr	₹16 Cr	₹19 Cr	₹17 Cr	₹17 Cr	₹15 Cr	₹14 Cr	₹13 Cr	₹12 Cr	₹18 Cr	₹13 Cr	₹15 Cr
₹2 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹49 L	₹28 L	₹31 L	₹29 L	₹24 L	₹16 L	₹16 L	₹12 L	₹35 L	₹29 L	₹21 L	₹44 L	₹48 L	₹32 L	₹41 L	₹30 L	₹25 L
₹23 Cr	₹20 Cr	₹20 Cr	₹24 Cr	₹23 Cr	₹21 Cr	₹20 Cr	₹20 Cr	₹18 Cr	₹23 Cr	₹20 Cr	₹18 Cr	₹16 Cr	₹15 Cr	₹13 Cr	₹16 Cr	₹14 Cr	₹14 Cr	₹11 Cr	₹11 Cr	₹10 Cr	₹8 Cr	₹15 Cr	₹9 Cr	-₹21 Cr
₹18 Cr	₹16 Cr	₹15 Cr	₹18 Cr	₹18 Cr	₹16 Cr	₹15 Cr	₹16 Cr	₹13 Cr	₹17 Cr	₹15 Cr	₹14 Cr	₹12 Cr	₹11 Cr	₹9 Cr	₹12 Cr	₹10 Cr	₹15 Cr	₹8 Cr	₹8 Cr	₹7 Cr	₹6 Cr	₹12 Cr	₹9 Cr	-₹23 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
—	—	—	—	—	—	—	—	—
₹11 Cr	₹10 Cr	₹10 Cr	₹10 Cr	₹11 Cr	₹6 Cr	₹6 Cr	₹6 Cr	₹9 Cr
₹20 Cr	₹5 Cr	₹5 Cr	₹3 Cr	₹2 Cr	₹0	₹0	₹0	₹0
₹551 Cr	₹490 Cr	₹435 Cr	₹389 Cr	₹382 Cr	₹193 Cr	₹203 Cr	₹187 Cr	₹117 Cr
₹551 Cr	₹490 Cr	₹435 Cr	₹389 Cr	₹382 Cr	₹193 Cr	₹203 Cr	₹187 Cr	₹117 Cr
₹581 Cr	₹506 Cr	₹450 Cr	₹402 Cr	₹395 Cr	₹199 Cr	₹210 Cr	₹194 Cr	₹125 Cr
₹0	₹0	₹0	₹11 L	₹44 L	₹83 L	₹1 Cr	₹6 Cr	₹18 Cr
-₹45 L	-₹28 L	-₹57 L	-₹2 Cr	-₹2 Cr	₹68 L	-₹66 L	-₹51 L	-₹74 L
₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹24 L	₹70 L	₹1 Cr	₹2 Cr	₹2 Cr
₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr
₹5 Cr	₹5 Cr	₹4 Cr	₹3 Cr	₹21 L	₹4 Cr	₹3 Cr	₹8 Cr	₹21 Cr
—	—	—	—	—	—	—	—	—
₹238 Cr	₹178 Cr	₹132 Cr	₹88 Cr	₹63 Cr	₹40 Cr	₹83 Cr	₹58 Cr	₹85 Cr
₹48 Cr	₹43 Cr	₹40 Cr	₹32 Cr	₹25 Cr	₹24 Cr	₹21 Cr	₹17 Cr	₹29 Cr
₹30 Cr	₹27 Cr	₹0	₹0	₹5 Cr	₹29 Cr	₹21 Cr	₹17 Cr	₹24 Cr
₹4 Cr	₹2 Cr	₹73 L	₹1 Cr	₹33 L	₹28 L	₹41 L	₹4 Cr	₹5 Cr
₹321 Cr	₹249 Cr	₹172 Cr	₹121 Cr	₹94 Cr	₹93 Cr	₹125 Cr	₹96 Cr	₹143 Cr
₹907 Cr	₹760 Cr	₹626 Cr	₹527 Cr	₹489 Cr	₹296 Cr	₹338 Cr	₹298 Cr	₹289 Cr
₹30 Cr	₹27 Cr	₹11 L	₹44 L	₹6 Cr	₹31 Cr	₹27 Cr	₹30 Cr	₹55 Cr
—	—	—	—	—	—	—	—	—
₹367 Cr	₹346 Cr	₹275 Cr	₹194 Cr	₹164 Cr	₹184 Cr	₹79 Cr	₹85 Cr	₹104 Cr
₹153 Cr	₹122 Cr	₹96 Cr	₹85 Cr	₹73 Cr	₹88 Cr	₹9 Cr	₹21 Cr	₹17 Cr
₹213 Cr	₹223 Cr	₹179 Cr	₹109 Cr	₹91 Cr	₹96 Cr	₹70 Cr	₹64 Cr	₹86 Cr
₹56 Cr	₹3 Cr	₹6 Cr	₹14 Cr	₹8 Cr	₹4 L	₹0	₹5 Cr	₹11 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹94 Cr	₹101 Cr	₹19 L
₹0	₹0	₹0	₹0	₹0	₹0	₹94 Cr	₹101 Cr	₹19 L
₹5 Cr	₹5 Cr	₹8 Cr	₹43 Cr	₹5 Cr	₹6 Cr	₹5 Cr	₹7 Cr	₹6 Cr
₹2 Cr	₹1 Cr	₹2 Cr	₹6 Cr	₹3 Cr	₹0	₹13 L	₹18 L	₹16 L
₹280 Cr	₹235 Cr	₹194 Cr	₹173 Cr	₹107 Cr	₹102 Cr	₹170 Cr	₹177 Cr	₹145 Cr
—	—	—	—	—	—	—	—	—
₹268 Cr	₹223 Cr	₹173 Cr	₹107 Cr	₹65 Cr	₹23 Cr	₹22 Cr	₹21 Cr	₹22 Cr
₹62 Cr	₹81 Cr	₹62 Cr	₹75 Cr	₹59 Cr	₹41 Cr	₹49 Cr	₹19 Cr	₹35 Cr
₹227 Cr	₹167 Cr	₹136 Cr	₹117 Cr	₹111 Cr	₹79 Cr	₹64 Cr	₹62 Cr	₹67 Cr
₹2 Cr	₹16 Cr	₹31 Cr	₹25 Cr	₹114 Cr	₹31 Cr	₹18 Cr	₹13 Cr	₹8 Cr
₹2 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹3 Cr	₹3 Cr	₹46 L	₹33 L	₹52 L
₹66 Cr	₹36 Cr	₹27 Cr	₹29 Cr	₹30 Cr	₹17 Cr	₹14 Cr	₹5 Cr	₹12 Cr
₹627 Cr	₹525 Cr	₹431 Cr	₹354 Cr	₹382 Cr	₹194 Cr	₹168 Cr	₹120 Cr	₹144 Cr
₹306 Cr	₹276 Cr	₹260 Cr	₹232 Cr	₹288 Cr	₹101 Cr	₹43 Cr	₹24 Cr	₹86 L
₹907 Cr	₹760 Cr	₹626 Cr	₹527 Cr	₹489 Cr	₹296 Cr	₹338 Cr	₹298 Cr	₹289 Cr
₹266	₹239	₹214	₹191	₹180	₹311	₹327	₹302	₹218
₹266	₹239	₹214	₹191	₹180	₹109	₹115	₹106	₹77

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent of Subsidiaries under liquidations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
₹87 Cr	₹80 Cr	₹77 Cr	₹57 Cr	₹46 Cr	₹22 Cr	₹25 Cr	₹76 Cr	₹20 Cr
₹37 Cr	₹18 Cr	₹7 Cr	₹7 Cr	₹10 Cr	₹36 Cr	₹17 Cr	-₹34 Cr	₹25 Cr
-₹4 Cr	-₹9 Cr	₹44 Cr	₹6 Cr	-₹38 Cr	-₹40 Cr	-₹4 Cr	-₹12 Cr	-₹5 Cr
₹120 Cr	₹89 Cr	₹128 Cr	₹71 Cr	₹18 Cr	₹18 Cr	₹38 Cr	₹31 Cr	₹40 Cr
₹105 Cr	₹68 Cr	₹109 Cr	₹61 Cr	₹9 Cr	₹11 Cr	₹25 Cr	₹19 Cr	₹35 Cr
-₹92 Cr	-₹74 Cr	-₹92 Cr	-₹14 Cr	-₹155 Cr	-₹20 Cr	-₹14 Cr	-₹5 Cr	-₹11 Cr
-₹13 Cr	₹1 Cr	-₹15 Cr	-₹44 Cr	₹130 Cr	₹78 L	-₹5 Cr	-₹6 Cr	-₹26 Cr
₹11 L	-₹5 Cr	₹2 Cr	₹3 Cr	-₹15 Cr	-₹8 Cr	₹5 Cr	₹7 Cr	-₹2 Cr
₹42 L	₹5 Cr	₹4 Cr	₹57 L	₹16 Cr	₹18 Cr	₹13 Cr	₹7 Cr	₹9 Cr
₹0	₹0	₹0	₹0	₹0	₹6 Cr	₹0	-₹1 Cr	₹0
₹54 L	₹42 L	₹5 Cr	₹4 Cr	₹57 L	₹16 Cr	₹18 Cr	₹13 Cr	₹7 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Windlas Biotech Share Price

879.60-30.05 (-3.30%)

-6.97% past 1 Year

Shareholding summary

Promoters

63.31%

FII

2.09%

DII

4.14%

3.1%

Others

27.36%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
63.31%	63.31%	61.90%	61.99%	61.99%	62.34%
2.09%	2.04%	0.60%	0.93%	1.11%	1.44%
4.14%	4.08%	4.72%	4.81%	5.05%	4.42%
3.10%	5.76%	7.08%	6.63%	6.39%	6.80%
27.36%	24.81%	25.70%	25.64%	25.46%	25.00%

Bulk & block deals

Name

Nk Securities Research Private Limited

Ajay Kumar Aggarwal

Samvitti Capital Private Limited Active Alpha Multicap

Graviton Research Capital Llp

Jainam Broking Limited

Graviton Research Capital Llp

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
11 Aug 2026	Purchase	11.10 Cr	₹935.99	1.19 L	Bulk	0.565229	NSE
11 Aug 2026	Sell	11.11 Cr	₹936.43	1.19 L	Bulk	0.565229	NSE
20 Feb 2025	Purchase	11.42 Cr	₹787.42	1.45 L	Bulk	0.691793	NSE
19 Feb 2025	Sell	7.89 Cr	₹683.49	1.15 L	Bulk	0.550467	NSE
01 Mar 2024	Sell	6.25 Cr	₹564.94	1.11 L	Bulk	0.527284	NSE
01 Mar 2024	Purchase	6.26 Cr	₹565.96	1.11 L	Bulk	0.527284	NSE
08 Feb 2024	Purchase	7.07 Cr	₹522.39	1.35 L	Bulk	0.644945	NSE
08 Feb 2024	Sell	7.07 Cr	₹522.27	1.35 L	Bulk	0.644945	NSE
02 Jan 2024	Purchase	7.67 Cr	₹511.50	1.50 L	Bulk	0.714817	NSE
02 Jan 2024	Sell	21.20 Cr	₹517.50	4.10 L	Bulk	1.952216	NSE

Insider trading & SAST

Client name

Icici Prudential Mutual Fund

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
10 Jun 2026	Other	Disposal	2.63	4.33	—	5.41 L	30 Jul 2024 - 13 May 2026	Market	9,13,135	SAST	29(2)	—
02 Aug 2024	Other	Disposal	2.32	6.96	—	5.04 L	20 Mar 2023 - 29 Jul 2024	Market	14,53,777	SAST	29(2)	—
21 Mar 2023	Other	Acquisition	2.01	9.27	—	3.75 L	20 Apr 2022 - 19 Mar 2023	Market	19,58,136	SAST	29(2)	—
21 Apr 2022	Other	Acquisition	0.15	7.26	—	32.87 K	19 Apr 2022	Market	15,83,045	SAST	29(2)	—
03 Nov 2021	Other	Acquisition	0.23	5.15	—	50 K	02 Nov 2021	Market	11,21,827	SAST	29(1)	—

Windlas Biotech Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Windlas Biotech Share Price

Windlas Biotech Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Windlas Biotech Share Price

Windlas Biotech Share Price

Oscillators

Moving averages

Windlas Biotech Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Windlas Biotech Share Price

Corporate Actions

Company details

Windlas Biotech Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Windlas Biotech Share Price

News

Windlas Biotech reports flat Q1 EBITDA, margin declines year on year

Windlas Biotech reports flat Q1 profit, revenue rises 19 percent year on year

Windlas Biotech - Quaterly Results

Windlas Biotech reports Profit after tax of 16.02 Crores, in the March 2026 quarter

Windlas Biotech normalises operations after temporary Uttarakhand labour strike disruption

Windlas Biotech announces Rs 47 crore share buyback via tender offer route

Windlas Biotech: Board Approves Share Buyback At Rs 1,000 Per Share Through Tender Offer

Windlas Biotech informs about outcome of postal ballot

Windlas Biotech Receives Show Cause Notice, Temporary Suspension of Codeine Cough Syrup Manufacturing.

Windlas Biotech - Quaterly Results

Windlas Biotech Q3 EBITDA Slightly Down YoY at Rs 24.40 Crores, Margin Contracts to 10.47%.

Windlas Biotech Q3FY26 Results: Revenue Up 18% YoY, Net Profit Marginally Down.

Windlas Biotech reports Profit after tax of 14.95 Crores, in the December 2025 quarter

Windlas Biotech informs about conference call

Windlas Biotech reports Profit after tax of 17.80 Crores, in the September 2025 quarter

Windlas Biotech informs about analyst meet

Windlas Biotech informs about outcome of board meeting

Windlas Biotech informs about results presentation

Windlas Biotech - Quaterly Results

Windlas Biotech - Quaterly Results

Windlas Biotech Ltd Share Price Today

Windlas Biotech Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator